{"name":"SepNet - Critical Care Trials Group","slug":"sepnet-critical-care-trials-group","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Metabolic","slug":"metabolic","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Actrapid® (Insulin)","genericName":"Actrapid® (Insulin)","slug":"actrapid-insulin","indication":"Type 1 diabetes mellitus","status":"phase_3"}]}],"pipeline":[{"name":"Actrapid® (Insulin)","genericName":"Actrapid® (Insulin)","slug":"actrapid-insulin","phase":"phase_3","mechanism":"Actrapid is a rapid-acting human insulin that binds to insulin receptors on cells to promote glucose uptake and utilization, lowering blood glucose levels.","indications":["Type 1 diabetes mellitus","Type 2 diabetes mellitus (when oral agents are insufficient)"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.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?oc=5","date":"2026-03-28","type":"pipeline","source":"Medical Dialogues","summary":"Albumin Safe but No Proven Survival Benefit in Septic Shock: JAMA - Medical Dialogues","headline":"Albumin Safe but No Proven Survival Benefit in Septic Shock: JAMA","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTE4tYXlob3dXdHlGMkpkWFE5dzFPOG1RNEdWaUhscldJTHRpTDRCMGlvQjB0SXVWT2JzNW13OEc5c3BkekNmU0xGWmtna3l0QldUWFBjWXpqd1cxQTJKTkZv?oc=5","date":"2024-06-13","type":"pipeline","source":"nature.com","summary":"Serum cytokine dysregulation signatures associated with COVID-19 outcomes in high mortality intensive care unit cohorts across pandemic waves and variants - nature.com","headline":"Serum cytokine dysregulation signatures associated with COVID-19 outcomes in high mortality intensive care unit cohorts ","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_3":1},"enrichmentLevel":2,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}